R. Goldberg

发表

The current state of molecular testing in the treatment of patients with solid tumors, 2019

Edward S. Kim, W. El-Deiry, R. Goldberg, 2019, CA: a cancer journal for clinicians.

Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.

D. Sargent, R. Goldberg, N. Foster, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.

D. Sargent, S. Thibodeau, R. Goldberg, 2012, JAMA.

Association of TP53 Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803

C. Compton, M. Bertagnolli, C. Atreya, 2013, Clinical Cancer Research.

Research Methods for Clinical Trials in Personalized Medicine: A Systematic Review

M. Kosorok, M. Davidian, A. Tsiatis, 2012 .

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Ludmila V. Danilova, L. Cope, A. Zaheer, 2017, Science.

Expression of Nuclear Factor-kappaB Family Proteins in Hepatocellular Carcinomas

R. Goldberg, W. Funkhouser, David F. Kashatus, 2007, Oncology.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

N. Petrelli, N. Wolmark, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303

Yusuke Nakamura, Chen Jiang, Kouros Owzar, 2011, Clinical Cancer Research.

Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer

P. Goodfellow, W. Frankel, S. Liyanarachchi, 2017, JAMA oncology.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Bert Vogelstein, Toby C. Cornish, Toby C Cornish, 2015, The New England journal of medicine.

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.

N. Petrelli, N. Wolmark, R. Goldberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803

C. Compton, M. Bertagnolli, S. Ogino, 2016, The oncologist.

A three-outcome design for phase II clinical trials.

D. Sargent, R. Goldberg, V. Chan, 2001, Controlled Clinical Trials.

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Daniel J Sargent, Dongsheng Tu, Pierre Laurent-Puig, 2003, The New England journal of medicine.

Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC).

G. Phillips, R. Goldberg, T. Bekaii-Saab, 2014 .

Frequency of loss of hMLH1 expression in colorectal carcinoma increases with advancing age

S. Kakar, S. Thibodeau, R. Goldberg, 2003, Cancer.

A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.

Tepper, J. Tepper, L. Caskey, 2010, Clinical colorectal cancer.

Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.

J. O'fallon, R. Goldberg, C. Loprinzi, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?

H. McLeod, R. Goldberg, J. L. Yen-Revollo, 2008, Clinical Cancer Research.

Nuclear factor κ-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy.

F. Wright, J. Tepper, L. Caskey, 2011, International journal of radiation oncology, biology, physics.

A systematic review of the use of quality of life measures in colorectal cancer research with attention to outcomes in elderly patients.

R. Goldberg, M. Pignone, H. Sanoff, 2007, Clinical colorectal cancer.

CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

R. Schilsky, M. Bertagnolli, R. Goldberg, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diabetes Mellitus Affects Response to Neoadjuvant Chemoradiotherapy in the Management of Rectal Cancer

J. Tepper, B. Calvo, A. Caudle, 2008, Annals of Surgical Oncology.

Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors.

Edward S. Kim, P. Philip, R. Goldberg, 2018 .

Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials.

R. Labianca, D. Sargent, R. Goldberg, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.

J. Sloan, R. Goldberg, A. Adjei, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction

R. Goldberg, L. Schaaf, M. Rothenberg, 2006, Clinical Cancer Research.

Colorectal cancer chemotherapy

R. Goldberg, S. Gill, R. Thomas, 2003 .

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

J. Sloan, J. Sloan, R. Goldberg, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials

D. Sargent, P. Laurent-Puig, R. Goldberg, 2017, JAMA oncology.

Role of Deficient DNAMismatch Repair Status in PatientsWith Stage III Colon Cancer Treated With FOLFOXAdjuvant Chemotherapy A Pooled Analysis From 2 Randomized Clinical Trials

D. Sargent, P. Laurent-Puig, R. Goldberg, 2017 .

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

M. Bertagnolli, M. Emond, R. Goldberg, 2014, Gastroenterology.

Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.

C. Compton, M. Bertagnolli, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intranasal Midazolam in Patients With Status

R. Goldberg, J. Kendall, M. Reynolds, 1997 .

Intranasal midazolam in patients with status epilepticus.

R. Goldberg, J. Kendall, M. Reynolds, 1997, Annals of Emergency Medicine.

Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses

W. Frankel, A. de la Chapelle, R. Goldberg, 2016, Genetics in Medicine.

Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative

P. Goodfellow, W. Frankel, A. de la Chapelle, 2021, JCO precision oncology.

Promising New Agents for Colorectal Cancer

R. Goldberg, Satya N. Das, K. Ciombor, 2018, Current Treatment Options in Oncology.

Programmed death-1 blockade in mismatch repair deficient colorectal cancer.

B. Vogelstein, J. Eshleman, L. Diaz, 2016 .

Surgery for Recurrent Colon Cancer: Strategies for Identifying Resectable Recurrence and Success Rates after Resection

T. Fleming, C. Tangen, R. Goldberg, 1998, Annals of Internal Medicine.

Intensive surveillance after stage II or III colorectal cancer: is it worth it?

R. Goldberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).

L. Schwartz, M. Bertagnolli, R. Goldberg, 2016 .

Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.

J. Meyerhardt, C. Fuchs, R. Goldberg, 2022, Journal of geriatric oncology.

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

M. Socinski, R. Goldberg, A. Ivanova, 2007, Cancer Chemotherapy and Pharmacology.

Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?

R. Goldberg, T. Bekaii-Saab, S. Mikhail, 2015, Oncotarget.

Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.

K. Kahn, J. Niland, J. Meyerhardt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher.

R. Goldberg, A. Venook, D. Moore, 2009, Gastrointestinal cancer research : GCR.

Cost implications of new treatments for advanced colorectal cancer

D. Sargent, J. Beck, R. Goldberg, 2009, Cancer.

Managing older patients with colorectal cancer.

R. Goldberg, H. Sanoff, H. Bleiberg, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.

D. Sargent, J. Donohue, R. Goldberg, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential versus combination therapy in the treatment of patients with advanced colorectal cancer.

R. Goldberg, U. Shah, 2008, Clinical colorectal cancer.

Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.

R. Goldberg, H. Lenz, A. Venook, 2007, Clinical colorectal cancer.

High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.

J. Berlin, R. Goldberg, D. Moore, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.

R. Goldberg, H. Lenz, A. Venook, 2005, Clinical colorectal cancer.

A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer.

R. Goldberg, B. O'Neil, A. Lucas, 2011, Clinical colorectal cancer.

First-line therapeutic strategies in metastatic colorectal cancer.

R. Goldberg, J. Davies, 2008, Oncology.

Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer

R. Schilsky, R. Goldberg, D. Reinke, 2006 .

Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer

R. Goldberg, S. Gill, 2004, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.

J. Sloan, M. Goetz, R. Goldberg, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.

J. Sloan, R. Goldberg, A. Adjei, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin in the Treatment of Colorectal Cancer

R. Goldberg, S. Alberts, S. Jacobson, 2002 .

Oxaliplatin in colorectal cancer: current studies.

R. Goldberg, 2000, Oncology.

Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.

N. Wolmark, R. Goldberg, J. Marshall, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

The Role of Adjuvant Therapy in the Elderly

R. Goldberg, Christina Wu, 2013, Current Colorectal Cancer Reports.

Managing choices for older patients with colon cancer: adjuvant therapy.

R. Goldberg, Christina Wu, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.

R. Goldberg, Po-Huang Lee, A. Ohtsu, 2012, Clinical colorectal cancer.

Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies

R. Goldberg, Po-Huang Lee, A. Ohtsu, 2012, Cancer medicine.

Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies.

C. Tournigand, R. Goldberg, M. Rothenberg, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessing the quality of initial consultations regarding adjuvant colon cancer therapy.

R. Goldberg, M. Pignone, H. Sanoff, 2010, Clinical colorectal cancer.

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

D. Sargent, S. Thibodeau, H. McLeod, 2010, Journal of Clinical Oncology.

What is the standard chemotherapy for colorectal cancer patients with resectable liver metastases?

R. Goldberg, B. O'Neil, 2009, Nature Clinical Practice Oncology.

Colon cancer in older adults.

R. Goldberg, H. Sanoff, L. Raftery, 2008, Seminars in Oncology.

Which strategies will lead to progress in the management of colorectal cancer?

R. Goldberg, 2007, Gastrointestinal cancer research : GCR.

On the state of the art of adjuvant chemotherapy for colon cancer.

R. Goldberg, B. O'Neil, 2007, Gastrointestinal cancer research : GCR.

Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow.

R. Goldberg, A. Beaven, 2006, Oncology.

Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.

J. Tepper, R. Goldberg, D. Ryan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of adjuvant therapy for colorectal cancer: are we overtreating our patients?

R. Goldberg, S. Gill, 2005, Nature Clinical Practice Oncology.

Optimal Delivery of Cytotoxic Chemotherapy for Colon Cancer

R. Goldberg, L. Raftery, 2010, Cancer journal.

Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib

K. Owzar, R. Goldberg, A. Ivanova, 2020, Molecular Cancer Therapeutics.

Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy.

R. Goldberg, M. O’connell, C. Erlichman, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials.

R. Goldberg, B. O'Neil, 2008, The oncologist.

Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can).

R. Goldberg, B. O'Neil, 2005, Seminars in oncology.

Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.

D. Sargent, C. Fuchs, R. Goldberg, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Current approaches to first-line treatment of advanced colorectal cancer.

R. Goldberg, 2004, Clinical colorectal cancer.

New developments in therapy for colorectal cancer

R. Goldberg, S. Gill, 2003, Current Oncology Reports.

Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived

R. Goldberg, B. O'Neil, 2003, Expert Opinion on Investigational Drugs.

Optimal use of the combination of irinotecan and 5-fluorouracil.

A. Benson, R. Goldberg, 2003, Seminars in oncology.

Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer.

R. Goldberg, T. Hobday, 2002, Clinical colorectal cancer.

Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program.

D. Sargent, R. Goldberg, J. Krook, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.

J. Sloan, R. Diasio, R. Goldberg, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy for colon cancer

R. Goldberg, Shaji K. Kumar, 2001 .

A Two-cohort Phase I Study of Weekly Oxaliplatin and Gemcitabine, Then Oxaliplatin, Gemcitabine, and Erlotinib During Radiotherapy for Unresectable Pancreatic Carcinoma

J. Tepper, R. Goldberg, A. Ivanova, 2013, American journal of clinical oncology.

Cetuximab in the treatment of colorectal cancer.

Richard L Schilsky, R. Schilsky, R. Goldberg, 2004, Clinical advances in hematology & oncology : H&O.

Surgery for Recurrent Colon Cancer

T. Fleming, C. Tangen, R. Goldberg, 1999 .

An embarrassment of riches: neoadjuvant therapy of rectal cancer.

J. Tepper, R. Goldberg, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.

W. Wood, R. Goldberg, A. Grothey, 2011, The oncologist.

Cancer-Associated Anorexia and Cachexia

R. Goldberg, C. Loprinzi, N. Burnham, 1992, Drugs.

NF- κ B is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiation

J. Tepper, L. Caskey, B. Calvo, 2011 .

Colorectal cancer.

R. Goldberg, S. Gill, A. W. Blackstock, 2007, Mayo Clinic proceedings.

Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.

D. Sargent, H. McLeod, R. Goldberg, 2010, Transactions of the American Clinical and Climatological Association.

NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial.

J. Buckner, D. Sargent, H. McLeod, 2009, The oncologist.

Outcomes in Patients with Obstructive Jaundice from Metastatic Colorectal Cancer and Implications for Management

M. Bloomston, R. Goldberg, T. Bekaii-Saab, 2014, Journal of Gastrointestinal Surgery.

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.

R. Goldberg, M. O’connell, H. Pitot, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Mayo/NCCTG Experience with 5-Fluorouracil and Leucovorin in Adjuvant Advanced Colorectal Cancer

D. Sargent, R. Goldberg, C. Erlichman, 2003 .

Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer.

S. Cha, D. Sargent, J. Sloan, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.

D. Sargent, S. Thibodeau, P. Laurent-Puig, 2015 .

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

D. Sargent, M. Ychou, R. Goldberg, 2013, The Lancet.

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Daniel J Sargent, D. Sargent, C. Fuchs, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germline Variation in Colorectal Risk Loci Does Not Influence Treatment Effect or Survival in Metastatic Colorectal Cancer

D. Sargent, H. McLeod, R. Goldberg, 2014, PloS one.

Accomplishments in 2007 in the treatment of advanced colorectal cancer.

A. Carrato, R. Goldberg, 2008, Gastrointestinal cancer research : GCR.

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine

S. Mandrekar, M. Goetz, R. Goldberg, 2013, Investigational New Drugs.

Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology.

H. Cohen, J. Buckner, J. Mandelblatt, 2020, Journal of geriatric oncology.

Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials.

J. Buckner, D. Sargent, R. Goldberg, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.

R. Goldberg, P. Schein, F. Smith, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer.

R. Goldberg, J. Tabernero, N. Meropol, 2009, Gastrointestinal cancer research : GCR.

Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.

J. Buckner, D. Sargent, S. Hillman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neuroendocrine differentiation is an independent prognostic factor in chemotherapy‐treated nonsmall cell lung carcinoma

S. Cha, R. Goldberg, J. Myers, 1996, Cancer.

Phase I Trial of Nanoparticle Albumin-Bound Paclitaxel in Combination with Gemcitabine in Patients with Thoracic Malignancies

D. Hayes, M. Socinski, R. Goldberg, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of EZN-2208 (PEG-SN38) with or without cetuximab in patients with metastatic colorectal cancer (CRC).

T. Ryan, R. Goldberg, T. Bekaii-Saab, 2012, Journal of Clinical Oncology.

What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings

J. Buckner, D. Sargent, S. Mandrekar, 2008 .

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.

J. Sloan, R. Marks, R. Goldberg, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581.

R. Schilsky, M. Bertagnolli, P. Friedman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.

J. O'fallon, R. Goldberg, C. Loprinzi, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In reply [4]

R. Goldberg, H. Sanoff, H. Bleiberg, 2007 .

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.

R. Labianca, D. Sargent, R. Goldberg, 2001, The New England journal of medicine.

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803)

R. Goldberg, L. Saltz, D. Hollis, 2004 .

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer.

C. Compton, S. Jewell, M. Bertagnolli, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803).

R. Goldberg, L. Saltz, D. Hollis, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pooled safety and efficacy analysis of the FOLFOX4 regimen (bi-monthly oxaliplatin plus fluorouracil/leucovorin) in elderly compared to younger patients with colorectal cancer.

C. Tournigand, D. Sargent, R. Goldberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

S. Cha, R. Labianca, D. Sargent, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

End points in advanced colon cancer clinical trials: a review and proposal.

D. Sargent, M. Buyse, R. Goldberg, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Future directions in adjuvant therapy for stage III colon carcinoma.

R. Goldberg, H. Pitot, 2001, Oncology.

Adjuvant chemotherapy for colon cancer

R. Goldberg, Shaji K. Kumar, 2001, Current oncology reports.

Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803.

J. Meyerhardt, A. Benson, C. Fuchs, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of primary (1{o}) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

J. Meyerhardt, R. Schilsky, M. Bertagnolli, 2016 .

Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.

D. Sargent, N. Wolmark, R. Goldberg, 2011, Journal of the National Cancer Institute.

N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study.

D. Sargent, C. Fuchs, R. Goldberg, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.

R. Goldberg, 2002, Clinical colorectal cancer.

A novel interaction of genotype, gender, and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803.

C. Compton, M. Bertagnolli, C. Atreya, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147).

D. Sargent, J. Sloan, R. Diasio, 2012 .

Body mass index (BMI) as a prognostic and predictive factor in stage II/III colon cancer: An analysis of the ACCENT database.

R. Labianca, D. Sargent, A. Benson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147.

D. Sargent, E. Basch, J. Sloan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)].

D. Sargent, S. Thibodeau, R. Goldberg, 2014 .

Outcomes in white (W) patients (pts) and those of African (A) descent receiving adjuvant therapy for colon cancer (CC)

D. Sargent, N. Wolmark, R. Goldberg, 2007 .

Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance).

D. Sargent, R. Goldberg, A. Shields, 2017 .

Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).

M. Bertagnolli, R. Goldberg, H. Lenz, 2017 .

A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer

D. Sargent, J. Sloan, H. McLeod, 2005 .

Cancer anorexia/cachexia.

R. Goldberg, C. Loprinzi, 1999, Cancer treatment and research.

Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer

R. Goldberg, T. Smyrk, N. Foster, 2021, JNCI cancer spectrum.

p27 Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803

M. Loda, C. Compton, S. Jewell, 2011 .

Should gemcitabine be used as adjuvant chemotherapy in patients with resectable pancreatic cancer?

R. Goldberg, B. O'Neil, 2007, Nature Clinical Practice Gastroenterology &Hepatology.

A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

J. Sloan, R. Goldberg, S. Alberts, 2005, Cancer Chemotherapy and Pharmacology.

Advances in Colorectal and Anal Cancer Treatment Based Upon Selected ASCO 2016 Presentations—Advances in Immunotherapy and Considering the Site of the Primary Tumor in Treatment Decisions

R. Goldberg, 2016 .

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248.

R. Weinshilboum, M. Goetz, R. Goldberg, 2007, Clinical colorectal cancer.

Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesophageal cancers.

P. Philip, R. Goldberg, H. Lenz, 2019, Journal of Clinical Oncology.

Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer

P. Philip, R. Goldberg, H. Lenz, 2019, Clinical Cancer Research.

Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC).

P. Philip, A. Barzi, R. Goldberg, 2018 .

Cancer-associated anorexia and cachexia. Implications for drug therapy.

R. Goldberg, C. Loprinzi, N. Burnham, 1992, Drugs.

Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.

J. Sloan, R. Goldberg, A. Adjei, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database.

C. Bokemeyer, E. Van Cutsem, R. Goldberg, 2022, European journal of cancer.

Prevalence and prognostic significance of neuroendocrine differentiation in colorectal carcinomas

R. Goldberg, J. Krook, R. Lloyd, 1998, Endocrine pathology.

Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer.

J. Jett, R. Goldberg, C. Loprinzi, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Colorectal cancer treatment in older patients.

R. Goldberg, H. Sanoff, 2007, Gastrointestinal cancer research : GCR.

Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology.

J. Ajani, P. Philip, R. Goldberg, 2007, Gastrointestinal cancer research : GCR.

Cetuximab-associated infusion reactions: pathology and management.

R. Goldberg, D. Patel, 2006, Oncology.

Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.

R. Goldberg, J. Kugler, R. Levitt, 1994, Gynecologic oncology.

Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets

P. Philip, R. Goldberg, H. Lenz, 2022, Oncogene.

501OCALGB/SWOG 80405: PHASE III TRIAL OF IRINOTECAN/5-FU/LEUCOVORIN (FOLFIRI) OR OXALIPLATIN/5-FU/LEUCOVORIN (MFOLFOX6) WITH BEVACIZUMAB (BV) OR CETUXIMAB (CET) FOR PATIENTS (PTS) WITH EXPANDED RAS ANALYSES UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM (MCRC)

R. Schilsky, M. Bertagnolli, R. Goldberg, 2014 .

Relationship between MLH1, PMS2, MSH2 and MSH6 gene‐specific alterations and tumor mutational burden in 1057 microsatellite instability‐high solid tumors

Edward S. Kim, R. Goldberg, H. Lenz, 2020, International journal of cancer.

Molecular Characterization of Appendiceal Goblet Cell Carcinoid

P. Philip, R. Goldberg, H. Lenz, 2020, Molecular Cancer Therapeutics.

Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database.

N. Wolmark, R. Goldberg, A. Grothey, 2020, Journal of the National Cancer Institute.

Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Oxaliplatin in the Treatment of Colorectal Cancer

R. Goldberg, S. Alberts, S. Jacobson, 2002 .

Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101.

C. Willett, C. Fuchs, J. Tepper, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer

R. Goldberg, D. Tu, M. Moore, 2005, British Journal of Cancer.

A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.

D. Sargent, R. Goldberg, H. Pitot, 2003, International journal of radiation oncology, biology, physics.

Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.

S. Cha, D. Sargent, D. Moore, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study.

S. Cha, D. Sargent, D. Moore, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581.

S. Jewell, M. Bertagnolli, R. Goldberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Daniel J Sargent, Christophe Tournigand, Eduardo Diaz-Rubio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU

D. Sargent, P. Philip, R. Goldberg, 2005 .

Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy

D. Sargent, P. Philip, R. Goldberg, 2005 .

Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.

N. Wolmark, R. Goldberg, A. Grothey, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-0019CALGB/SWOG 80405: PHASE III TRIAL OF IRINOTECAN/5-FU/LEUCOVORIN (FOLFIRI) OR OXALIPLATIN/5-FU/LEUCOVORIN (MFOLFOX6) WITH BEVACIZUMAB (BV) OR CETUXIMAB (CET) FOR PATIENTS (PTS) WITH KRAS WILD-TYPE (WT) UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON

R. Schilsky, M. Bertagnolli, R. Goldberg, 2014 .

The ARCAD advanced colorectal cancer database-open for business.

D. Sargent, M. Buyse, R. Goldberg, 2012 .

Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database.

C. Tournigand, R. Goldberg, V. Heinemann, 2020 .

N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study.

D. Sargent, C. Fuchs, R. Goldberg, 2004, Journal of Clinical Oncology.

Colorectal cancer: Irinotecan therapy—following a trail of breadcrumbs?

R. Goldberg, B. O'Neil, 2009, Nature Reviews Gastroenterology &Hepatology.

Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.

N. Wolmark, E. Van Cutsem, R. Goldberg, 2019, Journal of Clinical Oncology.

Somatic DNA mutations, MSI status, mutational load (ML): Association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance).

M. Bertagnolli, R. Goldberg, H. Lenz, 2017 .

Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

M. Bertagnolli, R. Goldberg, H. Lenz, 2017 .

Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.

A. Benson, J. Galon, R. Goldberg, 2022, JCO precision oncology.

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

D. Sargent, A. Benson, J. Galon, 2018 .

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).

D. Sargent, A. Benson, J. Galon, 2017 .

Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.

E. Van Cutsem, R. Goldberg, D. Haller, 2020 .

PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.

B. Vogelstein, J. Eshleman, L. Diaz, 2016 .

Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer.

D. Sargent, R. Goldberg, J. Krook, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer.

A. Benson, R. Goldberg, P. Enzinger, 2010 .

Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).

J. Sloan, R. Goldberg, A. Adjei, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Rapid reporting and review of an increased incidence of a known adverse event.

D. Sargent, R. Goldberg, J. Krook, 2000, Journal of the National Cancer Institute.

Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia

D. Sargent, R. Goldberg, K. Rowland, 2002, International journal of gastrointestinal cancer.

Molecular profile of BRCA-mutated biliary tract cancers

P. Philip, W. El-Deiry, R. Goldberg, 2020, ESMO Open.

pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5fu)/cpt-11, 5fu/oxaliplatin (oxal), or Cpt-11/oxal therapy for advanced colorectal cancer (crc): Results from an intergroup trial : 1013

D. Sargent, S. Thibodeau, H. McLeod, 2003 .

A case of oxaliplatin-related posterior reversible encephalopathy syndrome.

R. Goldberg, B. O'Neil, M. Skelton, 2007, Clinical colorectal cancer.

Reply to J.N. Primrose et al and C.-H. Köhne.

B. Nordlinger, R. Goldberg, G. Poston, 2015, Journal of Clinical Oncology.

Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial Aggregation

D. Sargent, J. Hopper, S. Thibodeau, 2005, Clinical Cancer Research.

Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.

J. Jett, J. Sloan, R. Goldberg, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147

D. Sargent, S. Thibodeau, R. Goldberg, 2010 .

A clinical trial of biochemical modulation of 5‐fluorouracil with N‐phosphonoacetyl‐L‐aspartate and thymidine in advanced gastric and anaplastic colorectal cancer

R. Goldberg, J. Laurie, J. Krook, 1990, Cancer.

Colorectal Tumour Microsatellite Instability Test Results: Perspectives from Patients

D. Bowen, S. Thibodeau, J. Sloan, 2004, Hereditary cancer in clinical practice.

Measurable or assessable disease in lung cancer trials: does it matter?

J. Jett, R. Goldberg, J. Krook, 1994, Journal of Clinical Oncology.

Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group.

R. Goldberg, C. Loprinzi, P. Burch, 1990, Seminars in oncology.

Highlights in Gastrointestinal (Colorectal) Cancer Treatment: The Primary Tumor Sidedness Debate and Advances in Immunotherapy.

R. Goldberg, K. Ciombor, 2016, JAMA Oncology.

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.

R. Goldberg, L. Saltz, D. Hollis, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Commentary (Goldberg/O'Neil): Neoadjuvant Therapy for Gastric Cancer

R. Goldberg, B. O'Neil, 2005 .

Optimal First-Line Therapy for Metastatic Adenocarcinoma of the Esophagus

R. Goldberg, S. Mukherjee, M. Malla, 2022, Current treatment options in oncology.

Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib

M. Ychou, R. Goldberg, H. Lenz, 2013 .

Transdermal clonidine for ameliorating post-orchiectomy hot flashes.

J. O'fallon, R. Goldberg, C. Loprinzi, 1994, The Journal of urology.

' Phase J, study of the matrix metalloproteinase inhibitor, BAY 12-956^

J. Sloan, R. Goldberg, S. Alberts, 2001 .

A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).

Cristina Santos, R. Goldberg, J. Tabernero, 2022, European journal of cancer.

Phase II Evaluation of Continuous-Infusion 5-Fluorouracil, Leucovorin, Mitomycin-C, and Oral Dipyridamole in Advanced Measurable Pancreatic Cancer: A North Central Cancer Treatment Group Trial

R. Goldberg, P. Burch, C. Cobau, 2000, American journal of clinical oncology.

Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.

J. Sloan, R. Goldberg, S. Alberts, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor

B. Scheithauer, J. O'fallon, T. Cascino, 1996, Journal of Neuro-Oncology.

Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.

R. Goldberg, C. Erlichman, 1998, Oncology.

Dietary fat in relation to all‐cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405

J. Meyerhardt, E. Giovannucci, R. Goldberg, 2022, International journal of cancer.

Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG's phase III trials N9741 and N9841.

D. Sargent, R. Goldberg, A. Grothey, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion.

R. Goldberg, P. Woolley, P. Schein, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).

P. Laurent-Puig, R. Goldberg, T. Smyrk, 2019, Journal of Clinical Oncology.

Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2014 .

Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702

J. Meyerhardt, R. Goldberg, A. Shields, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Irinotecan-induced neutropenia and UGT1A1*28: Does dose matter?

H. McLeod, R. Goldberg, J. Hoskins, 2007 .

UGT1A1*28, toxicity and outcome in advanced colorectal cancer: Results from Trial N9741.

D. Sargent, H. McLeod, R. Goldberg, 2006, Journal of Clinical Oncology.

Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303.

M. Bertagnolli, P. Friedman, R. Goldberg, 2011, Journal of Clinical Oncology.

Randomized trial of cyclophosphamide, methotrexate, and 5‐fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer

Sin-Ho Jung, L. Hartmann, J. Ingle, 1994, Cancer.

Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer Care.

R. Holcombe, R. Goldberg, C. Verschraegen, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Current strategies in previously untreated advanced colorectal cancer.

R. Goldberg, Shannon K Penland, 2004, Oncology.

Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity

D. Sargent, H. McLeod, C. Fuchs, 2005 .

Time course of regorafenib-associated adverse events in the phase III CORRECT study.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.

D. Sargent, R. Goldberg, A. Grothey, 2011, The oncologist.

BASIC–ALIMENTARY TRACT The CpG Island Methylator Phenotype and Chromosomal Instability Are Inversely Correlated in Sporadic Colorectal Cancer

C. Compton, C. Boland, R. Goldberg, 2007 .

Platinum neurotoxicity pharmacogenetics

Howard L McLeod, H. McLeod, R. Goldberg, 2009, Molecular Cancer Therapeutics.

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).

M. Bertagnolli, P. Wirapati, R. Goldberg, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.

P. Philip, R. Goldberg, H. Lenz, 2018, The oncologist.

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

D. Sargent, R. Goldberg, A. Grothey, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.

C. Compton, D. Kerr, M. Bertagnolli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology.

J. Ajani, R. Goldberg, H. Lenz, 2007, Gastrointestinal cancer research : GCR.

First-Line Treatment Strategies to Improve Survival in Patients with Advanced Colorectal Cancer

R. Goldberg, S. Gill, 2004, Drugs.

Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance)

J. Meyerhardt, C. Fuchs, R. Goldberg, 2019, Clinical Cancer Research.

Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer

J. Meyerhardt, H. McLeod, C. Fuchs, 2019, Cancer Causes & Control.

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

Joseph G Ibrahim, Howard L McLeod, J. Ibrahim, 2007, Journal of the National Cancer Institute.

Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.

J. Sloan, R. Goldberg, C. Erlichman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)

D. Sargent, R. Goldberg, A. Shields, 2016, The Oncologist.

Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers

P. Philip, R. Goldberg, H. Lenz, 2021, Molecular Cancer Therapeutics.

Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer

P. Philip, R. Goldberg, H. Lenz, 2021, Oncogene.

Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer

D. Sargent, S. Thibodeau, R. Goldberg, 2008, Clinical Cancer Research.

Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.

Daniel J Sargent, Daniel G Haller, Joel E Tepper, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy for metastatic colorectal cancer.

R. Goldberg, 2006, The oncologist.

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers

John L Marshall, P. Philip, R. Goldberg, 2018, Molecular Cancer Research.

Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors.

P. Philip, R. Goldberg, H. Lenz, 2018, The oncologist.

WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype

R. Goldberg, H. Lenz, A. Shields, 2020, Cancers.

How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer?

R. Goldberg, K. Ciombor, S. Haraldsdottir, 2014, Current Colorectal Cancer Reports.

Recent advances in treatment of metastatic colorectal cancer

R. Goldberg, S. Haraldsdottir, 2012 .

Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.

D. Sargent, R. Goldberg, L. Burgart, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers.

D. Schaid, D. Sargent, S. Thibodeau, 1999, Journal of the National Cancer Institute.

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.

Donna Niedzwiecki, Federico Innocenti, Fang-Shu Ou, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.

C. Compton, M. Bertagnolli, R. Goldberg, 2007, Gastroenterology.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

J. Meyerhardt, R. Schilsky, M. Bertagnolli, 2017, JAMA.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

D. Sargent, M. Teufel, M. Ychou, 2015, The Lancet. Oncology.

KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

D. Sargent, S. Thibodeau, R. Goldberg, 2014, Clinical Cancer Research.

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

D. Sugarbaker, C. Willett, C. Reed, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X.

J. Potter, D. Seminara, J. Hopper, 2005, JAMA.

Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2

A. Sigurdsson, K. Stefánsson, P. Sulem, 2017, Nature Communications.

Hypermutated Tumors and Immune Checkpoint Inhibition

R. Goldberg, K. Ciombor, 2018, Drugs.

Recent therapeutic advances in the treatment of colorectal cancer.

R. Goldberg, Christina Wu, K. Ciombor, 2015, Annual review of medicine.

Time course of regorafenib-associated adverse events in the phase III CORRECT study

M. Ychou, R. Goldberg, H. Lenz, 2013 .

Review article: colorectal cancer chemotherapy.

R. Goldberg, S. Gill, R. Thomas, 2003, Alimentary pharmacology & therapeutics.

A phase 2 trial of gemcitabine, 5‐fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma

J. Tepper, R. Goldberg, D. Hollis, 2011, Cancer.

Chemoradiation therapy in the management of gastrointestinal malignancies.

R. Goldberg, A. McRee, A. Wang, 2011, Future oncology.

Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis.

D. Sargent, J. Ajani, J. Tepper, 2002, International Journal of Radiation Oncology, Biology, Physics.

Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130.

Charles R. Thomas, D. Sargent, J. Donohue, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers: A Secondary Analysis of 2 Randomized Clinical Trials

D. Sargent, S. Thibodeau, K. Pogue-Geile, 2017, JAMA oncology.

Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.

D. Schaid, R. Goldberg, C. Loprinzi, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)

Daniel J. Sargent, Olivier Bouché, Alberto Sobrero, 2012 .

Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.

D. Spiegelman, J. Meyerhardt, A. Benson, 2013, Journal of the National Cancer Institute.

A flexible design for multiple armed screening trials

D J Sargent, R M Goldberg, D. Sargent, 2001, Statistics in medicine.

Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)

M. Bertagnolli, P. Friedman, R. Goldberg, 2013, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer : Results from CALGB 80303 ( Alliance )

M. Bertagnolli, P. Friedman, R. Goldberg, 2013 .

The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer

P. Stafford, R. Goldberg, H. Lenz, 2021, Clinical Cancer Research.

The impact of ARID1A mutation on molecular characteristics in colorectal cancer.

P. Philip, R. Goldberg, H. Lenz, 2020, European journal of cancer.

Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer.

R. Goldberg, H. Lenz, A. Shields, 2019, The oncologist.

A Blueprint to Advance Colorectal Cancer Immunotherapies

Vanessa M. Hubbard-Lucey, L. Diaz, E. Jaffee, 2017, Cancer Immunology Research.

Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal Cancer: Further Validation of a Potentially Practice-Changing Variable.

R. Goldberg, K. Ciombor, 2017, JAMA Oncology.

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.

D. Sargent, M. Delorenzi, S. Thibodeau, 2015, Gastroenterology.

Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors.

Daniel J Sargent, John Hopper, Bharati Bapat, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples

M. Washington, R. Goldberg, N. Deane, 2016, Scientific Reports.

Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2014, Clinical colorectal cancer.

Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.

D. Sargent, S. Thibodeau, M. Bertagnolli, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.

R. Schilsky, M. Bertagnolli, P. Friedman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803

D. Spiegelman, J. Meyerhardt, A. Benson, 2011, Clinical Cancer Research.

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

C. Compton, S. Jewell, M. Bertagnolli, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405

J. Meyerhardt, A. Benson, C. Fuchs, 2020, JNCI cancer spectrum.

p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803

M. Loda, C. Compton, S. Jewell, 2009, Clinical Cancer Research.

p 27 Kip 1 in Stage IIIColon Cancer : Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group BProtocol 89803

C. Compton, S. Jewell, M. Bertagnolli, 2009 .

Colorectal cancer prognosis among patients with inflammatory bowel disease.

R. Goldberg, E. Loftus, P. Limburg, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.

J. Sloan, R. Goldberg, S. Alberts, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144.

D. Sargent, R. Goldberg, M. O’connell, 2009, Clinical colorectal cancer.

Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.

Henry C. Pitot, Daniel J. Sargent, Stephen K. Williamson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients.

D. Sargent, S. Thibodeau, R. Goldberg, 2006, Gastroenterology.

Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer.

R. Goldberg, K. Ciombor, 2014, Hepatic oncology.

The continuum of care: a paradigm for the management of metastatic colorectal cancer.

A. Benson, E. Van Cutsem, R. Diasio, 2007, The oncologist.

Cost‐effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany

R. Goldberg, B. Göke, T. Kirchner, 2012, International Journal of Cancer.

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.

R. Labianca, D. Sargent, M. Buyse, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas

M. Bloomston, G. Phillips, R. Goldberg, 2015, Annals of Surgical Oncology.

Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.

D. Sargent, P. Laurent-Puig, R. Goldberg, 2015 .

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

R. Schilsky, R. Goldberg, H. Hurwitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

D. Sargent, F. Penault-Llorca, R. Goldberg, 2017, Journal of the National Cancer Institute.

Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.

D. Sargent, S. Thibodeau, R. Goldberg, 2015, Journal of the National Cancer Institute.

Commentary: Disclosure in oncology -- to whom does the truth belong?

W. Wood, R. Goldberg, M. McCabe, 2009, The oncologist.

Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy

A. Degramont, R. Labianca, D. Sargent, 2013, Cancer.

C. Tournigand, R. Labianca, J. Ajani, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

New Drugs in the Frontier of Treatment of Metastatic Colorectal Cancer

R. Goldberg, Christina Wu, 2012, Current Colorectal Cancer Reports.

Colorectal clinical trials: what is on the horizon?

R. Goldberg, D. Ahn, 2016, Future oncology.

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

C. Tournigand, D. Sargent, M. Buyse, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.

J. Meyerhardt, A. Benson, M. Bertagnolli, 2011, Journal of the National Cancer Institute.

KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803

J. Meyerhardt, A. Benson, M. Bertagnolli, 2009, Clinical Cancer Research.

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Daniel J Sargent, Daniel G Haller, Marc Buyse, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer.

J. Meyerhardt, C. Fuchs, R. Goldberg, 2020, JAMA oncology.

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.

L. Schwartz, J. Meyerhardt, M. Bertagnolli, 2019, JAMA oncology.

Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer.

J. O'fallon, R. Goldberg, C. Loprinzi, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2010 Staging System for Colon and Rectal Carcinoma

C. Compton, L. Sobin, M. Washington, 2011, Annals of Surgical Oncology.

Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

C. Tournigand, M. Buyse, C. Bokemeyer, 2019, JAMA network open.

A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors

R. Goldberg, A. Ivanova, B. O'Neil, 2014, Cancer Chemotherapy and Pharmacology.

Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer

P. Goodfellow, W. Frankel, A. de la Chapelle, 2018, JAMA oncology.

Therapeutic advances in pancreatic cancer: miles to go before we sleep.

R. Goldberg, T. Bekaii-Saab, 2015, Journal of the National Cancer Institute.

FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?

R. Goldberg, T. Bekaii-Saab, 2013, The oncologist.

Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.

D. Sargent, R. Goldberg, A. Grothey, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)

P. Philip, A. Barzi, R. Goldberg, 2020, Clinical Cancer Research.

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2014, Journal of the National Cancer Institute.

A review of oxaliplatin and its clinical use in colorectal cancer

R. Goldberg, A. Grothey, 2004, Expert opinion on pharmacotherapy.

Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

D. Sargent, R. Goldberg, A. Grothey, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma.

R. Goldberg, M. Morse, H. Sanoff, 2011, Gastrointestinal cancer research : GCR.

What is the optimal neo-adjuvant treatment for liver metastasis?

M. Bloomston, R. Goldberg, Christina Wu, 2013, Therapeutic Advances in Medical Oncology.

Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

J. Meyerhardt, C. Willett, C. Fuchs, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.

D. Sargent, H. McLeod, R. Goldberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

R. Goldberg, M. Tempero, P. Enzinger, 2009, Journal of Clinical Oncology.

Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.

J. Meyerhardt, M. Bertagnolli, C. Fuchs, 2021, JAMA.

A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.

J. Sloan, R. Goldberg, H. Pitot, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II study of amonafide in patients with recurrent glioma

Jan C. Buckner, B. Scheithauer, J. O'fallon, 2005, Journal of Neuro-Oncology.

Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance).

D. Sargent, S. Thibodeau, R. Goldberg, 2017, Journal of gastrointestinal oncology.

Association of family history with cancer recurrence and survival among patients with stage III colon cancer.

J. Meyerhardt, M. Bertagnolli, C. Fuchs, 2008, JAMA.

Thymidylate Synthase Expression in Colon Carcinomas with Microsatellite Instability

D. Sargent, S. Thibodeau, R. Goldberg, 2006, Clinical Cancer Research.

Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer.

D. Sargent, P. Johnston, R. Goldberg, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update on Anti-angiogenesis Therapy in Colorectal Cancer

R. Goldberg, K. Ciombor, 2015, Current Colorectal Cancer Reports.

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials

A. Degramont, J. Meyerhardt, C. Bokemeyer, 2022, JNCI Cancer Spectrum.

A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.

J. Sloan, R. Goldberg, S. Alberts, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial

R. Goldberg, H. Lenz, J. Tabernero, 2016 .

Diagnosis of digestive system tumours

M. Rugge, M. Salto‐Tellez, P. Schirmacher, 2020, International journal of cancer.

Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.

D. Sargent, C. Fuchs, R. Goldberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A north central cancer treatment group Phase II trial of 9‐aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma

D. Sargent, R. Goldberg, J. Krook, 2000, Cancer.

Adjuvant therapy for node-negative colon cancer

R. Goldberg, S. Gill, 2002 .

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.

J. Berlin, R. Goldberg, J. Marshall, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

D. Sargent, P. Philip, R. Goldberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma

P. Philip, W. El-Deiry, R. Goldberg, 2020, ESMO Open.

A Phase I and Pharmacologic Study of Pyrazoloacridine (NSC 366140) and Carboplatin in Patients with Advanced Cancer

J. Sloan, R. Goldberg, S. Alberts, 2002, Investigational New Drugs.

CPT-11 for bile-duct and gallbladder carcinoma

R. Goldberg, L. Burgart, S. Alberts, 2002, International journal of gastrointestinal cancer.

Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?

R. Goldberg, 2015, The oncologist.

Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma.

D. Sargent, J. Sloan, R. Goldberg, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy a nd Q uality-of-Life D ata A re R elated i n a P hase I I Trial o f O ral C hemotherapy i n P reviously U ntreated P atients With M etastatic C olorectal C arcinoma

D. Sargent, J. Sloan, R. Goldberg, 2002 .

Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.

C. Tournigand, D. Sargent, R. Stephens, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Translating Research Into Practice: The Role of Provider-based Research Networks in the Diffusion of an Evidence-based Colon Cancer Treatment Innovation

B. Weiner, R. Goldberg, B. Qaqish, 2012, Medical Care.

Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer.

Stephanie A. Bien, A. Joshi, Wei Sun, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

J. Meyerhardt, A. Benson, E. Giovannucci, 2015, Journal of the National Cancer Institute.

Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.

C. Tournigand, D. Sargent, R. Goldberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study

James Y. Dai, H. Brenner, J. Chang-Claude, 2021, Cancer Epidemiology, Biomarkers & Prevention.

Targeted agents in the treatment of pancreatic cancer: history and lessons learned

R. Goldberg, J. Bendell, 2007, Current opinion in oncology.

A pilot study assessing social support among cancer patients enrolled on clinical trials: a comparison of younger versus older adults

L. Hartmann, T. Rummans, J. Sloan, 2010, Cancer Management and Research.

Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)

J. Meyerhardt, C. Fuchs, R. Goldberg, 2019, JNCI cancer spectrum.

Prostate cancer incidence in males with Lynch syndrome

W. Frankel, R. Goldberg, T. Bekaii-Saab, 2013, Genetics in Medicine.

Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer

P. Stafford, R. Goldberg, H. Lenz, 2021, Oncogene.

Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability

D. Sargent, S. Thibodeau, R. Goldberg, 2007, International journal of cancer.

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Daniel J Sargent, Greg Yothers, Daniel G Haller, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

A. Benson, R. Goldberg, P. Enzinger, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials

C. Tournigand, C. Fuchs, R. Goldberg, 2020, Clinical trials.

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

A. Benson, J. Galon, R. Goldberg, 2020, JNCI Cancer Spectrum.

Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer

J. Meyerhardt, D. Sargent, J. Sloan, 2005, Cancer Epidemiology Biomarkers & Prevention.

Impact of smoking on patients with stage III colon cancer

J. Meyerhardt, A. Benson, R. Goldberg, 2010, Cancer.

Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405.

J. Meyerhardt, K. Van Loon, C. Fuchs, 2013, Clinical colorectal cancer.

Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.

Brian Bot, Greg Yothers, Qian Shi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?

B. Nordlinger, R. Goldberg, G. Poston, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic therapy for metastatic colorectal cancer: current options, current evidence.

R. Goldberg, H. Kelly, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)

D. Sargent, S. Thibodeau, R. Goldberg, 2015, Clinical Cancer Research.

Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).

H. Cohen, E. Lamont, R. Schilsky, 2015, Journal of the National Cancer Institute.

A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma

R. Goldberg, J. Krook, H. Wieand, 1995, Cancer.

Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.

D. Sargent, R. Goldberg, L. Saltz, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.

David M. Thomas, D. Sargent, A. Bleyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

C. Tournigand, D. Sargent, C. Bokemeyer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is ATP (adenosine 5'-triphosphate), like STP, a performance-enhancing additive for the tanks of cancer patients?

J. Sloan, R. Goldberg, C. Loprinzi, 2000, Journal of the National Cancer Institute.

Chemotherapy in elderly patients with colorectal cancer.

R. Goldberg, C. Köhne, G. Folprecht, 2008, The oncologist.

Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer

R. Goldberg, Z. Wainberg, C. Montagut, 2018, ESMO Open.

TREATMENT OF METASTATIC COLORECTAL CANCER Review of recent advances

R. Goldberg, S. Gill, J. Davies, 2005 .

Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.

D. Sargent, R. Goldberg, T. Karrison, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).

J. Tepper, R. Goldberg, D. Niedzwiecki, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).

D. Sargent, R. Diasio, Adam M. Lee, 2014, Journal of the National Cancer Institute.

Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.

Daniel J Sargent, Qian Shi, Marc Buyse, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741

J. Meyerhardt, D. Sargent, C. Fuchs, 2008, Clinical Cancer Research.

A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC)

C. Tournigand, D. Sargent, R. Goldberg, 2007 .

Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis

J. Hecht, C. Bokemeyer, E. Van Cutsem, 2021, Therapeutic advances in medical oncology.

MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial

M. Bertagnolli, M. Emond, P. Rabinovitch, 2014, PloS one.

Advances in the treatment of metastatic colorectal cancer.

R. Goldberg, 2005, The oncologist.

The landscape of POLE variants in colorectal and endometrial tumors: Correlation with microsatellite instability (MSI) and tumor mutation burden (TMB).

R. Goldberg, A. Shields, J. Marshall, 2020 .

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).

R. Schilsky, M. Bertagnolli, T. Davison, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

C. Tournigand, D. Sargent, R. Simes, 2018, Journal of the National Cancer Institute.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).

D. Sargent, R. Diasio, Adam M. Lee, 2016, Pharmacogenetics and genomics.

Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147

D. Sargent, P. Newcomb, R. Goldberg, 2016, International Journal of Cancer.

A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).

R. Schilsky, R. Goldberg, G. Abou-Alfa, 2010, The oncologist.

Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials.

D. Sargent, P. Laurent-Puig, R. Goldberg, 2020, JCO precision oncology.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

R. Goldberg, M. O’connell, C. Erlichman, 2001, The New England journal of medicine.

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

R. Labianca, J. Meyerhardt, E. Oki, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.

J. Meyerhardt, M. Bertagnolli, C. Fuchs, 2020 .

Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology.

B. Vogelstein, L. Diaz, T. Greten, 2016 .

Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGPs).

Edward S. Kim, R. Goldberg, H. Lenz, 2019, Journal of Clinical Oncology.

Comparison of adverse events during 5‐fluorouracil versus 5‐fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer

M. Schymura, R. Goldberg, D. Schrag, 2012, Cancer.

The evolving role of radiation in pancreatic cancer

R. Goldberg, F. Fekrmandi, Sagila George, 2023, Frontiers in Oncology.

Conversion Therapy for Initially Borderline/Unresectable Metastases in Colon Cancer: What Is the Best Neoadjuvant Chemotherapy?

R. Goldberg, S. Haraldsdottir, 2017, Current Colorectal Cancer Reports.

A Single Institutional Experience with Panitumumab in Metastatic Colorectal Cancer

R. Goldberg, T. Bekaii-Saab, Lai Wei, 2012 .

A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB

R. Schilsky, H. McLeod, R. Goldberg, 2007 .

Lessons Learned from the Edrecolomab Story: How a Checkered Past Became a Checkered Flag for Monoclonal Antibodies in Colorectal Cancer Therapy

R. Goldberg, 2005, Oncology Research and Treatment.

Management of infusion reactions in clinical trials and beyond: the US and EU perspectives.

F. Lordick, R. Goldberg, A. Cmelak, 2009, Oncology.

Cancer and Leukemia Group B Gastrointestinal Cancer Committee

M. Bertagnolli, J. Tepper, R. Goldberg, 2006, Clinical Cancer Research.

N9741: Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC)

D. Sargent, C. Fuchs, R. Goldberg, 2007 .

Mortality associated with daily bolus 5‐fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin

D. Sargent, R. Goldberg, R. Morton, 2004, Cancer.

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405

J. Meyerhardt, C. Fuchs, R. Goldberg, 2020, JNCI cancer spectrum.

Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma

R. Goldberg, M. Morse, H. Sanoff, 2008 .

Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer

Wei Chen, J. Datta, R. Goldberg, 2017, Oncotarget.

Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.

P. Laurent-Puig, R. Goldberg, T. Smyrk, 2020, European Journal of Cancer.

Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.

J. Berlin, E. Van Cutsem, R. Goldberg, 2014, Clinical colorectal cancer.

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

R. Labianca, J. Meyerhardt, M. Shah, 2020, European Journal of Cancer.

Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147.

D. Sargent, J. Sloan, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New targeted therapies in gastrointestinal cancers

R. Goldberg, S. Gill, Rebecca R. Thomas, 2003, Current treatment options in oncology.

Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741.

J. Meyerhardt, D. Sargent, C. Fuchs, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary Analysis of Cancer and Leukemia Group B (CALGB) 80003: A Phase II Trial of Gemcitabine, 5-Fluorouracil (5FU), and Radiation Therapy (RT) in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma

C. Fuchs, J. Tepper, R. Goldberg, 2005 .

Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405.

J. Meyerhardt, K. Van Loon, C. Fuchs, 2021, Journal of the National Cancer Institute.

Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.

N. Tomita, T. Yamanaka, N. Wolmark, 2021, Journal of the National Cancer Institute.

Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.

R. Labianca, R. Goldberg, C. Lepage, 2022, European journal of cancer.

Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.

J. Sloan, R. Goldberg, A. Adjei, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The ARCAD clinical trials program: an update and invitation.

Daniel J Sargent, Marc Buyse, Alastair Matheson, 2012, The oncologist.

Optimal Management of Metastatic Colorectal Cancer

R. Goldberg, A. McRee, 2011, Drugs.

Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.

G. Weiss, R. Goldberg, D. Haller, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The ARCAD advanced colorectal cancer database--open for business.

D. Sargent, M. Buyse, R. Goldberg, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

When the family requests withholding the diagnosis: who owns the truth?

W. Wood, R. Goldberg, M. McCabe, 2010, Journal of oncology practice.

Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer

T. Ryan, R. Goldberg, A. Ivanova, 2018, Cancer.

Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.

C. Tournigand, D. Sargent, M. Buyse, 2014 .

Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX)

D. Sargent, R. Goldberg, A. Grothey, 2007, Cancer.

5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study.

S. Cha, D. Sargent, R. Goldberg, 2005, Clinical colorectal cancer.

Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.

D. Sargent, C. Fuchs, R. Goldberg, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival outcomes used to generate version 9 American Joint Committee on Cancer staging system for anal cancer

M. Washington, J. Palefsky, K. Goodman, 2023, CA: a cancer journal for clinicians.

Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

Daniel J Sargent, Somnath Sarkar, D. Sargent, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.

J. Meyerhardt, C. Fuchs, R. Goldberg, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Prospective Multi-Institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer and Leukemia Group B Study 89903

R. Schilsky, R. Goldberg, A. Venook, 2009, Annals of Surgical Oncology.

A Phase II Prospective Multi-institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer and Leukemia Group B Study 89903

R. Schilsky, R. Goldberg, A. Venook, 2007, Annals of Surgical Oncology.

Comprehensive population-wide detection of Lynch syndrome in Iceland.

A. Sigurdsson, K. Stefánsson, P. Sulem, 2016 .

Genetic polymorphisms, toxicity, and response rate in African Americans (AA) with metastatic colorectal cancer (MCRC) compared to Caucasians (C) when treated with IFL, FOLFOX or IROX in Intergroup N9741.

D. Sargent, H. McLeod, C. Fuchs, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.

C. Tournigand, D. Sargent, J. Hecht, 2013 .

Optimizing adjuvant therapy for colon cancer: Ongoing investigations

R. Goldberg, B. O'Neil, H. Kelly, 2005 .

Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance)

Wei Sun, P. Newcomb, U. Peters, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Optimum chemotherapy regimens for neoadjuvant therapy of hepatic colorectal metastases

R. Goldberg, J. Davies, 2010, Journal of Surgical Oncology.

Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer

Z. Trajanoski, R. Goldberg, H. Lenz, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Preliminary evidence of relationship between genetic markers and oncology patient quality of life (QOL).

D. Sargent, J. Sloan, H. McLeod, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database.

Qian Shi, Daniel J. Sargent, Fang-Shu Ou, 2017 .

Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials.

D. Sargent, S. Thibodeau, R. Goldberg, 2016 .

How we treat metastatic colon cancer in older adults.

R. Goldberg, H. Sanoff, 2013, Journal of Geriatric Oncology.

Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): Results from Intergroup Trial N9741.

J. Meyerhardt, D. Sargent, C. Fuchs, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost‐effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first‐line therapy for metastatic colorectal carcinoma

D. Sargent, B. Hillner, C. Fuchs, 2005, Cancer.

Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer

P. Novotny, J. Sloan, C. Fuchs, 2023, Cancer control : journal of the Moffitt Cancer Center.

Molecular characterization of appendiceal goblet cell carcinoid.

P. Philip, R. Goldberg, H. Lenz, 2020 .

Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials

Sumithra J. Mandrekar, Henry C. Pitot, Daniel J. Sargent, 2011, Clinical Cancer Research.

Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.

P. Philip, W. El-Deiry, R. Goldberg, 2019, Journal of Clinical Oncology.

Influence of Erythropoietin on Transfusion Requirements in Patients Receiving Preoperative Chemoradiotherapy for Rectal Cancer

R. Goldberg, T. Witzig, 1999 .

Associations of physical activity with survival and progression in metastatic colorectal cancer: Results from CALGB 80405 (Alliance).

J. Meyerhardt, M. Bertagnolli, C. Fuchs, 2017 .

Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC) - lessons learned from N9741

D. Sargent, R. Goldberg, A. Grothey, 2007 .

Survival outcomes used to validate version 9 of the American Joint Committee on Cancer staging system for appendiceal cancer

S. Kakar, M. Washington, R. Goldberg, 2023, CA: a cancer journal for clinicians.

Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer.

R. Goldberg, Shannon K Penland, 2004, Clinical colorectal cancer.

Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial

J. Meyerhardt, E. Giovannucci, C. Atreya, 2020, JAMA network open.

Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets

R. Goldberg, H. Lenz, A. Shields, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Randomized phase 2 study of pegylated SN‐38 (EZN‐2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer

T. Ryan, R. Goldberg, T. Bekaii-Saab, 2013, Cancer.

Modified gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer (MPC): A single-institution experience.

R. Goldberg, T. Bekaii-Saab, S. Mikhail, 2015 .

LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: Results of CALGB 80402

R. Goldberg, D. Niedzwiecki, S. Wadler, 2008 .

The impact of young age on survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program

D. Sargent, R. Goldberg, L. Saltz, 2013 .

A phase I dose escalation study of irinotecan (CPT-11), oxaliplatin (Oxal), and capecitabine (Cap) within three UGT1A1 TA promoter cohorts (6/6, 6/7, and 7/7)

S. Mandrekar, M. Goetz, R. Goldberg, 2005 .

Comprehensive molecular profiling of IDH1/2 mutant biliary cancers (BC).

R. Goldberg, H. Lenz, A. Shields, 2020 .

A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy

T. Ryan, R. Goldberg, A. Ivanova, 2016 .

Targeted therapies: Cetuximab, chemotherapy and KRAS status in mCRC

R. Goldberg, S. Gill, 2009, Nature Reviews Clinical Oncology.

Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma.

L. Hartmann, R. Goldberg, R. Levitt, 1994, Gynecologic Oncology.

The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005.

R. Labianca, K. Haustermans, E. Van Cutsem, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Genome‐wide study of genetic polymorphisms predictive for outcome from first‐line oxaliplatin‐based chemotherapy in colorectal cancer patients

J. Chang-Claude, M. Hoffmeister, P. Seibold, 2023, International journal of cancer.

Impact of age and comorbidities on treatment effect, tolerance, and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203.

J. Meyerhardt, R. Goldberg, A. Venook, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials

P. Laurent-Puig, E. Van Cutsem, R. Goldberg, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Scan? Cure? Sure!

R. Goldberg, D. Ryan, 2011, The oncologist.

Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance)

D. Sargent, P. Newcomb, R. Goldberg, 2018, Cancer Epidemiology, Biomarkers & Prevention.

Direct cost-survival analysis of therapies for metastatic colorectal cancer.

D. Sargent, J. Beck, R. Goldberg, 2006, Journal of Clinical Oncology.

Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer?

R. Goldberg, 1998, Seminars in oncology.

Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients

P. Philip, W. El-Deiry, R. Goldberg, 2021, npj Precision Oncology.

LBA10CALGB/SWOG 80405: ANALYSIS OF PATIENTS UNDERGOING SURGERY AS PART OF TREATMENT STRATEGY

R. Schilsky, M. Bertagnolli, R. Goldberg, 2014 .

A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603

R. Goldberg, T. Bekaii-Saab, D. Hollis, 2008 .

Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303)

K. Owzar, E. Gottlin, M. Campa, 2012, Cancer.

Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.

J. Berlin, E. Van Cutsem, R. Goldberg, 2014, Clinical colorectal cancer.

Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803.

J. Meyerhardt, A. Benson, C. Fuchs, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303

R. Goldberg, M. Mulcahy, D. Schrag, 2007 .

Treatment of metastatic colorectal cancer.

R. Goldberg, J. Davies, 2011, Seminars in oncology.

Cetuximab, chemotherapy and KRAS status in mCRC.

R. Goldberg, S. Gill, 2009, Nature reviews. Clinical oncology.

Bolus versus infusion regimens of etoposide and cisplatin in treatment of non-small cell lung cancer: a study of the North Central Cancer Treatment group.

T. Therneau, J. Jett, R. Goldberg, 1990, Journal of the National Cancer Institute.

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

M. Bertagnolli, M. Emond, R. Goldberg, 2014, Gastroenterology.

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

D. Sargent, S. Thibodeau, H. McLeod, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial.

J. Buckner, D. Sargent, H. McLeod, 2009, The oncologist.

Cost implications of new treatments for advanced colorectal cancer

D. Sargent, J. Beck, R. Goldberg, 2009, Cancer.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

N. Petrelli, N. Wolmark, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results.

R. Schilsky, A. Benson, R. Goldberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer

J. Meyerhardt, H. McLeod, C. Fuchs, 2019, Cancer Causes and Control.

Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors.

D. Sargent, J. Hopper, S. Thibodeau, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer

J. Meyerhardt, D. Sargent, J. Sloan, 2005, Cancer Epidemiology Biomarkers & Prevention.

Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.

C. Compton, M. Bertagnolli, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs

R. Goldberg, Lai Wei, S. Fernández, 2017, The Oncologist.

Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.

D. Sargent, M. Buyse, C. Fuchs, 2013 .

The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy

R. Goldberg, T. Bekaii-Saab, T. Williams, 2017, American Journal of Clinical Oncology.

p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803

M. Loda, C. Compton, S. Jewell, 2009, Clinical Cancer Research.

Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.

C. Fuchs, R. Goldberg, H. Hurwitz, 2005, Clinical advances in hematology & oncology : H&O.

Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).

P. Philip, W. El-Deiry, R. Goldberg, 2019, Journal of Clinical Oncology.

Phase II evaluation of menogaril in patients with advanced cervical carcinoma

R. Goldberg, G. Malkasian, J. Laurie, 1991, Investigational New Drugs.

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

J. Sloan, R. Goldberg, H. Pitot, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Reply to L. Casadaban et al.

R. Schilsky, M. Bertagnolli, T. Davison, 2017, Journal of Clinical Oncology.

Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance)

J. Meyerhardt, R. Goldberg, A. Shields, 2023, Cancer.

Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.

R. Schilsky, M. Bertagnolli, R. Goldberg, 2015 .

DNA ploidy is a stronger prognostic variable compared to microsatellite instability or 18q allelic loss in patients with stages II and III colon cancer

D. Sargent, S. Thibodeau, R. Goldberg, 2005 .

Dealing With Discordance: Managing a Case Where the Patient Looks Better and the CT Scan Looks Worse.

R. Goldberg, U. Shah, 2008, Gastrointestinal cancer research : GCR.

Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside.

T. Therneau, R. Goldberg, J. Gerstner, 1989, Medical and pediatric oncology.

Phase I study of the combination of everolimus (RAD001) with panitumumab in patients with refractory solid malignancies.

R. Goldberg, A. Ivanova, E. Dees, 2010 .

Phase I study of the combination of everolimus (RAD001) with 5FU/LV in patients with refractory solid malignancies.

R. Goldberg, A. Ivanova, E. Dees, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.